The role of cytokines in postmenopausal osteoporosis

Minerva Ginecologica

Volumn 66, Issue 4, 2014, Pages 391-407

  Brincat, S D ^a   Borg, M ^a   Camilleri, G ^a   Calleja Agius, J ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Bone; Bone and bones; Cytokines; Estrogen; Fractures; Menopause; Osteoporosis; Pharmacology

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLONY STIMULATING FACTOR 1; CYTOKINE; DENOSUMAB; ESTROGEN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BONE CELL; BONE MARROW; BONE MASS; BONE TURNOVER; DISEASE COURSE; DISEASE PREDISPOSITION; ESTROGEN DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSSIFICATION; OSTEOLYSIS; PHYSICAL STRENGTH; POSTMENOPAUSE OSTEOPOROSIS; STRENGTH;

EID: 84907533161     PISSN: 00264784     EISSN: 18271650     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Gur A, Denli A, Nas K., Colpan L, Cevik R, Altun R et al. Cytokines in the pathogenesis of postmenopausal osteoporosis and relationship between cytokines and osteocalcin. Journal of Medical School 2000; 27(1):47-54.
2. Salari P, Abdollahi M. A Comprehensive Review of the Shared Roles of Inflammatory Cytokines in Osteoporosis and Cardiovascular Diseases as Two Common Old People Problem - Actions Toward Development of New Drugs. International Journal of Pharmacology 2011; 7(5):552-567.
3. Manolagas SC, Jilka R. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995 Feb 2; 332(5):305-ll.
4. Troen BR. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol. 2003; 38:605-614.
5. Manolagas SC. Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocr Rev. 2000; 21(2):115-137.
6. Sahin G, Ozturk C, Bagis S., Bolgen Cimen O, Erdogan C. Correlation of serum cytokine levels with axial bone mineral density. Singapore Med J. 2002; 43(11):576-578.
7. Sampaio Lacativa P.G., Fleiuss de Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metab 2010; 54(2):123-132.
8. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. 2006 May; 116(5):1186-1194.
9. Rogers A, Saleh G, Hannon R.A., Greenfield D., Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002 Oct; 87(10):4470-4475.
10. Paciflci R. T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther. 2007; 9(2):102-105.
11. Mundy GR. Osteoporosis and Inflammation. Nutr Rev. Dec 2007(11);65(12): S147-S151.
12. Pfeilschifter J, Koditz R, Pfohl M., Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002; 23:90-199.
13. Zhao W, Liu Y, Cahill C.M., Yang W., Rogers JT, Xudong H. The role of T cells in osteoporosis, an update. Int J Clin Exp Pathol 2009; 2:544-552.
14. Cenci S, Toraldo G, Weitzmann M.N., Roggia C., Gao Y, Qian QP et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-y-induced class II transactivator. Proc Nad Acad Sci USA. 2003 Sept 2; 100(18):10405-10410.
15. Roggia C, Gao Y, Cenci S., Weitzmann MN, Toraldo G, Isaia G et al. Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which oestrogendeficiency induces bone loss in vivo. Proc Natl Acad Sci USA. 2001 Nov 20; 98(24):13960-13965.
16. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000; 100(10):1203-1204.
17. Clowes JA, Eghbali-Fatourechi GZ, McCready L., Oursler MJ, Khosla S, Riggs BL. Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporosis Int. 2009 May; 20(5):761-769.
18. McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Ther. 2007, 9(Suppl 1):S3.
19. Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology 2001 Dec 1; 142(12):5050-5055.
20. Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis inflammation and aging. Immunity & Aging 2005; 2:14-18.
21. Koka S, Petro TM, Reinhardt RA Estrogen inhibits interleukin-lâ-induced interleukin-6 production by human osteoblast-like cells. J Interferon Cytokine Res. 1998 Jul; 18(7):479-483.
22. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen E.N., Gram J., Beck-Nielsen H. Cytokines and bone loss, in a 5-year longitudinal study - hormone replacement therapy suppresses serum soluble interleukin-6 receptors and increases interleukin-I - receptor antagonist: the Danish osteoporosis prevention study. J Bone Miner Res. 2000; 15(8):1545-1554.
23. Giuliani N, Sansoni P, Girasole G., Vescovini V, Passed G, Passed M et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp 130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol. 2001 Mar; 36(3):547-557.
24. Scheidt-Nave C., Bismar H, Leidig-Bruckner G, Woitge H., Seibel MJ, Ziegler R et al. Serum Interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001; 56(5):2032-2042.
25. Gao Y, Grassi F, Ryan M.R., Terauchi M., Page K, Yang X et al. IFN-y stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007 Jan; 117(1):122-132.
26. Teitelbaum SL. Postmenopausal osteoporosis, T cells, and immune dysfunction. Proc Natl Acad Sci USA. 2004 Nov 30; 101(48): 16711-16712.
27. Cenci S, Weitzmann MN, Roggia C, Namba N., Novack D, Woodring J et al. Estrogen deficiency induces bone loss by enhancing T-cell production by TNF-a. J Clin Invest. 2000; 106(10):1229-1237.
28. Gonzalez EA. The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000; 15:945-950.
29. Bekker PJ, Holloway D, Nakanishi A., Arrighi M, Leese PT, Dunstan CR The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001 Feb; 16(2):348-360.
30. Vega D, Maalouf NM, Sakhaee K. The role of receptor activator of nuclear factor-KB (RANK)/RANK Ligand/ Osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007 Dec; 92(12):4514-4521.
31. Eghbali-Fatourechi G., Khosla S, Sanyal A., Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111:1221-1230.
32. Cretu A, Grigorie D, Neacsu E., Chiovschi SI. Implications of osteoprotegerin in postmenopausal osteoporosis. TMJ 2003; 53(3-4):226-229.
33. Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007 143; 143:31-48.
34. Yano K, Tsuda E, Washida N., Kobayashi F, Goto M, Harada A et al. Immunological characterization of circulation osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentration in postmenopausal women with osteoporosis. J Bone Miner Res. 1999; 14:518-527.
35. Lerner UH. Bone remodelling in post-menopausal osteoporosis. J Dent Res. 2006; 85(7):584-596.
36. Lewis DB, Liggitt HD, Effmann E.L., Motley ST, Teitelbaum SL, Jepsen KJ et al. Osteoporosis induced in mice by overproduction of interleukin 4. Proc Natl Acad Sci USA. 1993; 90:11618-11622.
37. Papanicolaou DA. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998 Jan 15; 128(2):127-137.
38. Simpson RJ, Hammacher A, Smith D.K., Matthew JM, Ward LD. Interleukin-6: Structure-function relationships. Protein Sci. 1997(6):929-955.
39. Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis inflammation and aging. Immunity & Aging 2005; 2:14-18.
40. Rachon D, Mysliwska J, Suchecka-Rachon K, Wieckiewics J., Mysliwski A. Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. J Endocrinol. 2002; 172:387-395.
41. Cioffi M, Esposito K, Vietri M.T., Gazzerro P., D'Auria A, Ardovino I et al. Cytokine pattern in postmenopause. Maturitas 2002; 41:187-192.
42. Weitzmann MN, Pacifici R. Role of the immune system in postmenopausal bone loss. Curr Osteoporos Rep. 2005; 3:92-97.
43. Lamarca M. The Role of Hormone Replacement Therapy (HRT) and Tibolone in the Prevention and Treatment of Postmenopausal Osteoporosis. In: Dionyssiotis Y Osteoporosis. In Tech, 2012.
44. Tanna N. Osteoporosis and its treatment. The Pharmaceutical Journal. 2005 Nov 5; 275:581-584.
45. Baqir W, Copeland C, Worsley A. Osteoporosis treatment and risk assessment. Clinical Pharmacist 2009 May; 1: 216-223.
46. Cole Z, Dennison E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 2008 May 12; 86:129-143.
47. European Medicines Agency. Forsteo [Internet]. European Union: European Medicines Agency; 2012 June 7 [cited 2012 Dec 7]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000425/human-med-000798.jsp&mid=WC0b01ac058001d124
48. Christiansen C. Menopausal osteoporosis: impact of sex steroid replacement. In: Adashi EY, Rock JA, Rosenwaks Z, editor. Reproductive endocrinology, surgery, and technology. USA: Lippincott-Raven; 1996.
49. Lewiecki EM. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. Journal of women's health. 2009; 18(10):1615-26.
50. Christenson ES, Jiang X, Kagan R., Schantz PF. Osteoporosis management in post-menopausal women. Minerva Ginecologica 2012 Jun; 64(3):181-94.
51. Abernethy K. The menopause and HRT. 2nd ed. China: Bailliere Tindall; 2002
52. Baqir W, Copeland C. Current and future drug treatments for the management of osteoporosis. The Pharmaceutical Journal 2010 April 3/10; 284: 345-346.
53. Rees M, Purdie D, editor. Management of the menopause: the handbook. 4th ed. The Netherlands: Royal Society of Medicine; 2006.
54. Goldstein SR, Siddhanti S, Ciaccia A.V., Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000; 6(3):212-224.
55. Gennari L, Merlotti D, De Paola V, Martini G, Nuti R. Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag. 2008 December; 4(6): 1229-1242.
56. De Villiers TJ. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. Climacteric 2010; 13:210-218.
57. Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging. 2011; 6:151-60.
58. Sharma S, Mahajan A, Kumar S., Tandon VR. Tibolone: A selective tissue oestrogenic activity regulator. JK Science October-December 2006; 8(4):229-230.
59. Mishell DR. Menopause - Endocrinology, Consequences of Estrogen deficiency, Effects of hormonal replacement therapy, Treatment regimens. In: Mishell RD, Stenhever MA, Droegemueller W, Herbst A, editor. Comprehensive Gynecology. 3rd ed. USA: Mosby; 1997.
60. Carey A, Carey B. Nutritional support for osteoporosis. In: Studd J, editor. The management of the menopause - annual review. London: The Parthenon Publishing Group; 1998
61. Akesson K. New approaches to pharmacological treatment of osteoporosis. Bull World Health Organ 2003; 81(9):657-663.
62. Bone HG, McClung MR, Roux C, Recker R.R., Eisman JA, Verbruggen N et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Mineral Res 2010 May; 25(5):937-947.
63. Rachner TD, Khosla S, Lorenz C Hofbauer LC. Osteoporosis: now and the future. Lancet 2011; 377: 1276-87.
64. Behrendt N. Matrix Proteases in Health and Disease. Germany: Wiley-VCH Verlag & Co; 2012
65. Baun L, Russell TM Overview of the Management of Osteoporosis in Women. US Pharm. 2011; 36(9):30-36.
66. Padhi D, Jang G, Stouch B., Fang L, Posvar E. Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody. Journal of Bone and Mineral Research 2011 Jan; 26(1): 19-26.
67. Brincat M, Calleja-Agius J, Vujovic S., Erel T, Gambacciani M, Lambrinoudaki I et al. EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas 2011 Jan; 68 (1): 98-101.
68. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of vertebral fractures: a metaanalysis of randomised trials. BMC Musculoskeletal Disorders 2001; 2:7-10.
69. Eriksen EF, Kassem M. The clinical problem of treating osteoporosis with estrogen. In: Studd J, editor. The management of the menopause - annual review. London: The Parthenon Publishing Group; 1998.
70. Schneider DL, Morton DJ Timing of postmenopausal estrogen for optimal bone mineral density. In: Studd J, editor. The management of the menopause - annual review. London: The Parthenon Publishing Group; 1998.
71. Hurd WW. Menopause. In: Berek JS, editor. Novak's Gynaecology. 12th edition ed. USA: Williams & Wilkins; 1996.
72. Calleja-Agius J., Brincat M. The effect of menopause on the skin and other connective tissues. Gynecological Endocrinology. 2012 Apr; 28(4):273-7.
73. Kaur K. Hormone Therapy [Internet]. WebMD LLC; © 1994-2012 [cited 2012 Dec 15]. Available from: http://emedicine.medscape.com/article/276104-overview#aw2aab6b5.
74. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360:942-944.
75. Calleja-Agius J., Brincat MP Hormone replacement therapy post Women's Health Initiative study: where do we stand? Curr Opin Obstet Gynecol 2008 Dec; 20(6):513-518.
76. Grbic JT, Landesberg R, Lin S., Mesenbrink P, Reid IR, Leung P et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial. JADA 2008 Jan; 139:32-40.
77. Bryan J. Benefits versus risks - the rise and fall of hormone replacement therapy. The Pharmaceutical Journal 2011 Jan 29; 286: 110-111.
78. Rizzoli R. Targeting RANKL in post-menopausal osteoporosis. European Musculoskeletal Review 2009:25-28.
79. Mensah KA, Li J, Schwarz EM The emerging field of osteoimmunology. Immunol Res. PMC 2010 Sep 7:1-15.
80. Cummings SR, Martin JS, McClung M.R., Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009 Aug 20; 361(8):756-765.
81. Tanaka S, Nakamura K, Takahasi N., Suda T. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunological Reviews 2005; 208:30-49.